News

Spending reached $4.86 trillion in 2023, a 7.5% increase from 2022 The growth in spending on hospital care was the highest since 1990.

Originally approved in 2009, Stelara patents began expiring in 2023, leading to an influx of recent biosimilars.

If approved, clesrovimab would be the first and only FDA approved single dose immunization for infants approved in time for next year's RSV season, which lasts from October to April.

Organon, the company behind Vtama, received FDA approval ahead of its scheduled date of March 12, 2025.

This latest approval is the second indication of the monoclonal antibody, Nemluvio. It was first approved in Aug. 2024 to treat patients with prurigo nodularis.

Here’s what you missed this week on Managed Healthcare Executive.

The new guidelines consist of 145 recommendations for treating and managing premature ovarian insufficiency syndrome, which affects an estimated 4% of women under the age of 40 worldwide.

Researchers at Brigham and Women’s Hospital Harvard Medical School looked at clinical trials and compared these biologics to placebos to see how their treatments improve and manage severe asthma.

Researchers have compiled a list of chemicals commonly found in plastics, including benzophenones, chlorinated paraffins and PFAS, known as “forever chemicals,” and they say there might be a connection to breast cancer.

Researchers are investigating the therapy as a treatment for B-cell malignancies, but they might also investigate as a treatment for multiple sclerosis and lupus.

Authorities have named Mangione, 26, as a person of interest in last week’s fatal shooting of United Healthcare CEO Brian Thompson in Manhattan. He was taken into custody at a McDonald’s in Altoona, Pennsylvania around 9 a.m. ET, officials said.

Here’s what you missed this week on Managed Healthcare Executive.

Aerobic exercise, particularly static exercises like yoga and stretching, performed 70 to 90 minutes three times a week over eight to 10 weeks, can significantly improve sleep disorders in menopausal women.

The combination of Columvi, gemcitabine and oxaliplatin is the first CD20xCD3 bispecific antibody to show positive results in a randomized diffuse large B-cell lymphoma phase 3 trial. The FDA’s decision is expected by July 20, 2025.

A systematic review and network meta-analysis examined research on four types of treatment for children with post-traumatic stress disorder. Trauma-focused cognitive behavioral therapy was the clear winner.

Thompson, who was on his way to attend an annual investor conference in Manhattan today, was shot after 6:45 a.m. in a targeted attack, police officials say.

The FDA has accepted a new drug application for aficamten, a new obstructive hypertrophic cardiomyopathy drug. A goal date has been set for Sept. 26, 2025.

Yesintek is the latest Stelara biosimilar to gain FDA approval and it will be available in February 2025.

A new nationwide study led by the Keck School of Medicine of USC aims to examine how type 1 diabetes impacts children's brain development and cognitive function, focusing on diverse participants and paving the way for early interventions and better diabetes management.

If granted, Tremfya will be approved to treat children ages six and under with severe plaque psoriasis and children ages five and under with juvenile psoriatic arthritis.

Here’s what you missed this week on Managed Healthcare Executive.

Paul Fronstin, director of Health Benefits Research at EBRI, discussed ERISA and trends in employer self-insurance during a conversation with Managed Healthcare Executive recently.

Paul Fronstin, director of Health Benefits Research at EBRI, spoke with MHE about the challenges employers face in incentivizing high-value healthcare while managing costs.

Poor balance and coordination are prominent features of Friedreich’s ataxia (FRDA). Czech researchers found that neuropsychiatric symptoms are also common among patients with FRDA.

Vutrisiran is the generic form of previously approved Amvuttra. The FDA’s target date for the treatment of transthyretin amyloidosis with cardiomyopathy is March 23, 2025.

Imkeldi is a new formulation of imatinib approved as a strawberry-flavored, shelf-stable liquid designed to be more appealing to a wider range of patients, pediatric patients included.